---
title: "Avalo Therapeutics, Inc. 1Q 2026: Revenue ($19.7M), Net income ($19.63M), EPS ($0.98) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286249429.md"
description: "Avalo Therapeutics, Inc. reported its first-quarter 2026 results, showing a revenue of $19.7M and a net loss of $19.63M, reflecting a year-over-year decline in both metrics. The company achieved positive Phase 2 results for its drug abdakibart in treating hidradenitis suppurativa, supporting plans for Phase 3 trials. R&D and G&A expenses increased to prepare for pivotal trials, and the company completed a $405M follow-on offering to fund operations through 2029."
datetime: "2026-05-13T11:11:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286249429.md)
  - [en](https://longbridge.com/en/news/286249429.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286249429.md)
---

# Avalo Therapeutics, Inc. 1Q 2026: Revenue ($19.7M), Net income ($19.63M), EPS ($0.98) — 10-Q Summary

Avalo Therapeutics, Inc. reported first-quarter 2026 results showing a wider comprehensive loss and net loss versus the prior-year quarter as the company increases spending to advance its clinical and regulatory programs.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

($19.7M)

($13.15M)

(49.9%)

Net income²

($19.63M)

($13.15M)

(49.3%)

Diluted EPS³

($0.98)

($1.25)

21.6%

_¹ Reported as “Comprehensive loss”. ² Reported as “Net loss”. ³ Reported as “loss per share of common stock, basic and diluted”._

**Business Highlights**

-   Clinical milestone: Positive Phase 2 LOTUS topline results in hidradenitis suppurativa (HS); primary endpoint met at both doses, supporting Phase 3 plans for abdakibart.
-   Pipeline strategy: Focus remains on advancing abdakibart toward registrational trials and evaluating additional indications and potential in‑licensing opportunities.
-   Operational scaling: R&D and G&A expenses increased to support pivotal preparations, manufacturing and clinical operations.
-   Capital position: Completed approximately $405M net follow‑on offering to fund operations and the Phase 3 program into 2029.

Original SEC Filing: Avalo Therapeutics, Inc. \[ AVTX \] - 10-Q - May. 13, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [AVTX.US](https://longbridge.com/en/quote/AVTX.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BMED.US](https://longbridge.com/en/quote/BMED.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [TMED.US](https://longbridge.com/en/quote/TMED.US.md)

## Related News & Research

- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)
- [<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>](https://longbridge.com/en/news/286807703.md)
- [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md)
- [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md)
- [<![CDATA[Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates]]>](https://longbridge.com/en/news/286787081.md)